Neurimmune Therapeutics AG, an early stage biotechnology firm specializing in developing antibody-based therapies for neurodegenerative conditions, entered an alliance on Alzheimer's disease with Biogen Idec worth up to $380 million in up-front and milestone payments. Neurimmune also would receive royalties on eventual product sales. (BioWorld International)